Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | PLD1 | Q13393 | 8/20 | 0.37 |
| ▸ | PLD2 | O14939 | 7/20 | 0.37 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.36 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.36 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2862082 | 0.90 | HTR4 (0.43) | NPSR1HTR4SIGMAR1 | |
| SCHEMBL2868696 | 0.90 | SIGMAR1 (0.44) | NPSR1HTR4SIGMAR1L3MBTL1 | |
| SCHEMBL2858188 | 0.89 | L3MBTL1 (0.44) | NPSR1SIGMAR1L3MBTL1 | |
| SCHEMBL2863108 | 0.89 | L3MBTL1 (0.44) | NPSR1SIGMAR1L3MBTL1 | |
| SCHEMBL2864346 | 0.88 | HTT (0.39) | NPSR1PLD1PLD2HTR4SIGMAR1 | |
| SCHEMBL2869035 | 0.88 | SMN1; SMN2 (0.43) | L3MBTL1 | |
| SCHEMBL2861377 | 0.87 | NPSR1 (0.38) | NPSR1PLD1PLD2HTR4ADRA1A | |
| SCHEMBL2856576 | 0.84 | NPSR1 (0.37) | NPSR1PLD1PLD2HTR4ADRA1A | |
| SCHEMBL2867838 | 0.84 | TSHR (0.48) | L3MBTL1 | |
| SCHEMBL2865817 | 0.83 | ALDH1A1 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7795267-B2 | Bicyclic piperazine compound having TGR23 antagonistic activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-14 | — | — | US | disclosed |
| US-20070072865-A1 | Bicyclic piperazine compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-29 | — | — | US | disclosed |
| EP-1661898-A1 | BICYCLIC PIPERAZINE COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2006-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072865-A1 | Bicyclic piperazine compound and use thereof | GPR3, FFAR3, LPAR3 | NPSR1 211/4885PLD1 1582/4885PLD2 547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.